1. Home
  2. SCNI

as of 12-12-2025 9:38am EST

$1.23
+$0.00
+0.07%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Chart Type:
Time Range:
Founded: 2003 Country:
Israel
Israel
Employees: N/A City: JERUSALEM
Market Cap: 4.6M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 41.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.26 EPS Growth: N/A
52 Week Low/High: $0.86 - $6.18 Next Earning Date: 11-24-2025
Revenue: $1,147,000 Revenue Growth: 303.87%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered SCNI Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 70.79%
70.79%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: